Lido Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 123.1% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,186 shares of the medical research company’s stock after purchasing an additional 2,310 shares during the quarter. Lido Advisors LLC’s holdings in Thermo Fisher Scientific were worth $811,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the company. BlackRock Inc. increased its stake in shares of Thermo Fisher Scientific by 2,692.1% during the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares during the period. KCG Holdings Inc. increased its stake in shares of Thermo Fisher Scientific by 42.1% during the first quarter. KCG Holdings Inc. now owns 25,700 shares of the medical research company’s stock worth $3,948,000 after buying an additional 7,611 shares during the period. Investment Centers of America Inc. purchased a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $200,000. Sterneck Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 14.1% during the first quarter. Sterneck Capital Management LLC now owns 3,650 shares of the medical research company’s stock worth $561,000 after buying an additional 450 shares during the period. Finally, National Asset Management Inc. increased its stake in shares of Thermo Fisher Scientific by 6.3% during the first quarter. National Asset Management Inc. now owns 2,905 shares of the medical research company’s stock worth $447,000 after buying an additional 172 shares during the period. 86.05% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently weighed in on TMO. Jefferies Group restated a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price on the stock. Barclays restated an “overweight” rating and set a $215.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Monday, September 25th. Argus restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Leerink Swann upped their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the stock an “outperform” rating in a research note on Monday, October 9th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. Thermo Fisher Scientific has a consensus rating of “Buy” and an average price target of $205.21.

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total value of $9,419,500.00. Following the transaction, the chief executive officer now directly owns 252,577 shares in the company, valued at $47,582,981.03. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.49% of the company’s stock.

Thermo Fisher Scientific Inc. (NYSE:TMO) opened at $193.57 on Tuesday. The company has a market cap of $77,099.38, a P/E ratio of 21.13, a price-to-earnings-growth ratio of 1.76 and a beta of 1.06. Thermo Fisher Scientific Inc. has a one year low of $139.88 and a one year high of $201.20. The company has a quick ratio of 0.81, a current ratio of 1.26 and a debt-to-equity ratio of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.31 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.24 by $0.07. The company had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm’s revenue was up 13.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.03 earnings per share. equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 9.36 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be paid a $0.15 dividend. The ex-dividend date is Thursday, December 14th. This represents a $0.60 annualized dividend and a yield of 0.31%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.19%.

WARNING: “Lido Advisors LLC Raises Stake in Thermo Fisher Scientific Inc. (TMO)” was published by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and reposted in violation of US & international copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/lido-advisors-llc-raises-stake-in-thermo-fisher-scientific-inc-tmo/1772990.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.